Lucius LuciDeucra Deucravacitinib 6mg

Product Information

• Product name: LuciDeucra Deucravacitinib 6mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Deucravacitinib
• Current strength: 6mg
• SKU: LU-ITEM-46
• Site category: psoriasis, other cancer

Product Summary

LuciDeucra Deucravacitinib 6mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Deucravacitinib is the active ingredient used for this product page. Public prescribing information for Deucravacitinib was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Deucravacitinib is an inhibitor of tyrosine kinase 2 (TYK2). TYK2 is a member of the Janus kinase (JAK) family. Deucravacitinib binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream activation of Signal Transducers and Activators of Transcription (STATs) as shown in cell-based assays. JAK kinases, including TYK2, function as pairs of homo- or heterodimers in the JAK-STAT pathways.

Reference Indications

Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for: the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use : Not recommended for use in combination with other potent immunosuppressants. the treatment of active psoriatic arthritis in adults. Limitations of Use : Deucravacitinib is not recommended for use in combination with other potent immunosuppressants.

Reference Dosage and Administration

Recommended dosage is 6 mg orally once daily, with or without food.

With this 6mg product, that corresponds to 1 x 6mg tablet when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Hypersensitivity Reactions: Hypersensitivity reactions, such as angioedema, have been reported. Discontinue if a clinically significant hypersensitivity reaction occurs. Infections: Deucravacitinib may increase the risk of infection. Avoid use in patients with active or serious infection. If a serious infection develops, discontinue Deucravacitinib until the infection resolves. Tuberculosis: Evaluate for latent or active TB prior to initiating treatment with Deucravacitinib. Malignancy: Malignancies including lymphomas were observed in clinical trials with Deucravacitinib. Consider the benefits and risks prior to initiating or continuing Deucravacitinib in patients with a malignancy. Rhabdomyolysis and Elevated CPK: Discontinue Deucravacitinib if markedly elevated CPK levels occur or myopathy is diagnosed or suspected .

Common Adverse Reactions and Monitoring

Plaque Psoriasis Clinical Trials The safety of Deucravacitinib was evaluated in two placebo- and active-controlled trials (Trial PSO-1 and Trial PSO-2) and an open-label extension trial in which subjects who completed Trial PSO-1 or Trial PSO-2 could enroll . All subjects randomized to placebo switched to Deucravacitinib at Week 16. All other subjects remained in their original treatment group until Week 24, at which point subjects could have continued on the same treatment or be switched to Deucravacitinib or placebo. The mean age of subjects was 47 years. The majority of subjects were White (87%) and male (67%).

Drug Interactions and Special Populations

Deucravacitinib is not recommended in patients with severe hepatic impairment (Child-Pugh C). All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Report pregnancies to the Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072. Data Animal data Deucravacitinib was administered orally during the period of organogenesis at doses of 5, 15, or 75 mg/kg/day in rats and 1, 3, or 10 mg/kg/day in rabbits. Deucravacitinib was not associated with embryo-fetal lethality or fetal malformations in either species.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: SOTYKTU public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.